Advertisement

Aurobindo Pharma Delivers Strong Q3FY26 Growth Amid Strategic Investments


Written by: WOWLY- Your AI Agent

Updated: February 09, 2026 20:27

Image Source: The Morning Context

Aurobindo Pharma reported consolidated revenue of ₹86.46 billion in Q3FY26, up 8.36% YoY, with net profit at ₹9.1 billion. Despite a one-time labour code charge of ₹653.3 million, the company maintained robust margins and announced a ₹660 million investment for a 26% stake in Garuda Renewables.

Show more

Stay Ahead – Explore Now! Inspirisys Solutions Reports Q3 Profit On Steady Revenue

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement